Published in World J Gastroenterol on June 14, 2012
The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol (2014) 1.23
PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol (2013) 1.18
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int (2015) 0.93
PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver Int (2013) 0.89
Host genetic variants in the pathogenesis of hepatitis C. Viruses (2012) 0.82
The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res (2014) 0.80
PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. PLoS One (2013) 0.79
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol (2016) 0.76
Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
The metabolic syndrome. Lancet (2005) 19.47
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 5.43
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
Hereditary hemochromatosis--a new look at an old disease. N Engl J Med (2004) 4.42
The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol (2007) 4.01
Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol (1962) 3.31
Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet (2009) 3.24
The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med (2000) 3.14
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2010) 2.95
A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med (1999) 2.86
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology (2010) 2.35
Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) (2009) 1.98
Hemochromatosis: an endocrine liver disease. Hepatology (2007) 1.96
I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology (2010) 1.70
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology (2010) 1.50
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology (2011) 1.49
Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol (2009) 1.48
Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology (2009) 1.47
Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med (2003) 1.33
Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology (2005) 1.17
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology (1992) 1.16
The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet (2004) 1.11
Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis (2002) 1.04
Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology (2007) 1.03
Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood (2008) 1.02
Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood (2001) 0.98
Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology (1994) 0.92
Haemochromatosis in patients with beta-thalassaemia trait. Br J Haematol (2000) 0.88
Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol (2009) 0.88
Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis (2005) 0.84
Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology (2010) 0.84
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2010) 2.95
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology (2015) 2.81
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology (2011) 2.36
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology (2009) 2.07
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol (2010) 1.78
Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol (2003) 1.74
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol (2011) 1.73
I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology (2010) 1.70
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol (2010) 1.68
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut (2012) 1.62
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol (2002) 1.62
Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol (2011) 1.59
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59
Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology (2010) 1.50
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. Intern Emerg Med (2006) 1.41
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol (2007) 1.41
Higher than expected progranulin mutation rate in a case series of Italian FTLD patients. Alzheimer Dis Assoc Disord (2009) 1.40
Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood (2010) 1.37
Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med (2008) 1.33
Increased serum ferritin is common in men with essential hypertension. J Hypertens (2002) 1.25
Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology (2002) 1.24
Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis (2007) 1.20
DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One (2008) 1.18
Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol (2008) 1.14
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol (2011) 1.09
Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol (2009) 1.09
Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis (2010) 1.08
Natural history of juvenile haemochromatosis. Br J Haematol (2002) 1.07
A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica (2010) 1.07
Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica (2007) 1.06
Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol (2010) 1.05
Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes (2008) 1.05
Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica (2007) 1.01
The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol (2012) 1.00
Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol (2008) 0.97
The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol (2009) 0.96
Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol (2013) 0.96
Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol (2007) 0.96
Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis (2009) 0.95
Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology (2006) 0.95
MR imaging of cerebral cortical involvement in aceruloplasminemia. AJNR Am J Neuroradiol (2005) 0.94
Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J (2004) 0.94
Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology (2003) 0.93
Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol (2012) 0.93
HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol (2009) 0.92